Eli Lilly’s experimental obesity drug, eloralintide, has shown promising results in an early-stage study, with some patients losing 11.5% of their body weight over 12 weeks. The data, published ahead of the American Diabetes Association conference, suggests that eloralintide is a strong contender for the next generation of obesity treatments.
Eloralintide belongs to a class of medicines that mimic the pancreatic hormone amylin, which slows digestion and suppresses hunger. The drug is currently being tested in mid-stage trials as a standalone treatment and in combination with Lilly’s blockbuster GLP-1 drug, tirzepatide.
Analysts at Cantor Fitzgerald and Jefferies have praised the data, noting that it suggests eloralintide may be a better alternative to existing treatments. Roche acquired Zealand Pharma’s long-acting amylin analogue, petrelintide, in March for up to $5.3 billion, but Lilly’s eloralintide is tracking better.
Eloralintide’s data at 12 weeks is also competitive compared to other drug classes such as GLP-1. The results are a significant improvement over expectations and suggest that the real successor to tirzepatide may be the combination of eloralintide and tirzepatide.
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-experimental-obesity-drug-shows-over-11-weight-loss-early-trial-2025-06-13